|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1704 USD | -2.07% |
|
-2.63% | -31.76% |
| May. 15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M | MT |
ReShape Lifesciences Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 11.24 million compared to USD 13.6 million a year ago. Net loss was USD 46.21 million compared to USD 63.15 million a year ago.
Basic loss per share from continuing operations was USD 108.9 compared to USD 288.97 a year ago. Diluted loss per share from continuing operations was USD 108.9 compared to USD 288.97 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -31.76% | 4.08M | |
| +12.50% | 229B | |
| +14.52% | 195B | |
| +17.51% | 142B | |
| +28.96% | 109B | |
| +3.27% | 64.85B | |
| +18.16% | 54.33B | |
| +7.63% | 52.09B | |
| +10.95% | 45.15B | |
| +5.10% | 37.39B |
RESHAPE LIFESCIENCES INC. 